Indivior Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Indivior Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $-320 of operating cash. Lower than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 95% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$-320Over the last 3 years, every $100 of reported profit came with $-320 of operating cash.
Lower than almost all Healthcare companies in United States.
Self-Funding Ratio
-1.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 60% of Healthcare companies in United States.
Cash Locked Ratio
$27For every $100 of sales, $27 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier.
More money tied up than 60% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$75Sales grew 38% in 3 years; of every extra $100 of sales, $75 became extra profit.
Higher than 76% of Healthcare companies in United States.
Asset Productivity Ratio
+38% / -32%In 3 years sales changed by +38% while total assets changed by -32%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-0.9×Operating cash was negative last year, while some debt falls due within a year.
Higher than 67% of Healthcare companies in United States.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 73% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 95% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Indivior Pharmaceuticals, Inc. owes $1.17 for every $1 it owns. Net profit rose 2900% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
12.7Investors pay $12.7 for every $1 of Indivior Pharmaceuticals, Inc.'s yearly profit, lower than 78% of Healthcare companies in United States.
P/B ratio
-20.15Indivior Pharmaceuticals, Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$4.2 BThe total market value of all of Indivior Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 82% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
NegativeIndivior Pharmaceuticals, Inc.'s net worth is negative ($207 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Owes vs Owns
1.17×Indivior Pharmaceuticals, Inc. owes $1.17 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Dividend yield
NoneIndivior Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Profit growth
+2900%Net profit rose 2900% in the year to Dec 2025.
Profit margin
16.9%Indivior Pharmaceuticals, Inc. keeps $17 of every $100 of revenue as net profit.
Cash quality
-0.1×Cash from Indivior Pharmaceuticals, Inc.'s business was -0.1× its reported profit in the year to Dec 2025 — the business used cash even though it reported a profit.
Interest cover
5.9×Indivior Pharmaceuticals, Inc.'s operating profit covered its interest costs 5.9 times in the year to Dec 2025.
Cash vs debt
Net debtIndivior Pharmaceuticals, Inc. had $156 M more debt than cash (net debt) at Dec 2025.
Questions
What is Indivior Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $12.7 for every $1 of Indivior Pharmaceuticals, Inc.'s yearly profit, lower than 78% of Healthcare companies in United States.
How much does Indivior Pharmaceuticals, Inc. owe compared with what it owns?
Indivior Pharmaceuticals, Inc. owes $1.17 for every $1 it owns, so it owes more than it owns, higher than 91% of Healthcare companies in United States.
Does Indivior Pharmaceuticals, Inc. pay a dividend?
No. Indivior Pharmaceuticals, Inc. does not currently pay a dividend.
Is Indivior Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 4% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.